Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

J Dziuba, P Alperin, J Racketa, U Iloeje… - Diabetes, Obesity …, 2014 - Wiley Online Library
Aims Dapagliflozin, a sodium‐glucose cotransporter 2 (SGLT‐2) inhibitor, has been shown
to lower glycated hemoglobin (HbA1c), weight, blood pressure and serum uric acid in …
被引用次数：128 相关文章

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.

J Dziuba, P Alperin, J Racketa… - Diabetes, Obesity & …, 2014 - search.ebscohost.com
Aims Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, has been shown to
lower glycated hemoglobin (HbA1c), weight, blood pressure and serum uric acid in clinical …

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.

J Dziuba, P Alperin, J Racketa, U Iloeje… - Diabetes, Obesity & …, 2014 - europepmc.org
Aims Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, has been shown to
lower glycated hemoglobin (HbA1c), weight, blood pressure and serum uric acid in clinical …

[引用][C] Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

J Dziuba, P Alperin, J Racketa, U Iloeje… - Diabetes, Obesity and …, 2014 - cir.nii.ac.jp
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy
on cardiovascular and microvascular outcomes | CiNii Research CiNii 国立情報学研究所 学術 …

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

J Dziuba, P Alperin, J Racketa… - Diabetes, obesity & …, 2014 - pubmed.ncbi.nlm.nih.gov
Aims Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, has been shown to
lower glycated hemoglobin (HbA1c), weight, blood pressure and serum uric acid in clinical …

Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

J Dziuba, P Alperin, J Racketa, U Iloeje… - Diabetes, Obesity and …, 2014 - infona.pl
Aims Dapagliflozin, a sodium‐glucose cotransporter 2 (SGLT‐2) inhibitor, has been shown
to lower glycated hemoglobin (HbA1c), weight, blood pressure and serum uric acid in …